GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Cash Conversion Cycle

Entheon Biomedical (XCNQ:ENBI) Cash Conversion Cycle : 0.00 (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Entheon Biomedical's Days Sales Outstanding for the three months ended in Feb. 2024 was 0.
Entheon Biomedical's Days Inventory for the three months ended in Feb. 2024 was 0.
Entheon Biomedical's Days Payable for the three months ended in Feb. 2024 was 0.
Therefore, Entheon Biomedical's Cash Conversion Cycle (CCC) for the three months ended in Feb. 2024 was 0.00.


Entheon Biomedical Cash Conversion Cycle Historical Data

The historical data trend for Entheon Biomedical's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Cash Conversion Cycle Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Cash Conversion Cycle
Get a 7-Day Free Trial - - - - -

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Entheon Biomedical's Cash Conversion Cycle

For the Biotechnology subindustry, Entheon Biomedical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Cash Conversion Cycle falls into.



Entheon Biomedical Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Entheon Biomedical's Cash Conversion Cycle for the fiscal year that ended in Nov. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+-
=0.00

Entheon Biomedical's Cash Conversion Cycle for the quarter that ended in Feb. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Entheon Biomedical Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines